NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
IMP Powers Reports Q3 Net Loss of ₹2.17 Crore; Auditors Issue Qualified Opinion
IMP Powers Limited reported a standalone net loss of ₹217.10 lakhs for the quarter ended December 31, 2025, a significant increase from the ₹108.86 lakhs loss in the prior year's quarter. Revenue from operations remains extremely low at just ₹12.76 lakhs for the quarter, though up slightly from ₹8.14 lakhs year-on-year. The statutory auditors have issued a qualified opinion, highlighting concerns over unconfirmed trade receivables, lack of impairment testing on assets, and improper inventory valuation. For the nine-month period, the company's total loss has reached ₹630.78 lakhs, indicating deep financial distress.
முக்கிய அம்சங்கள்
Net loss for Q3 FY26 widened to ₹217.10 lakhs from ₹108.86 lakhs in Q3 FY25.Revenue from operations remains negligible at ₹12.76 lakhs for the quarter.Auditors issued a qualified opinion citing failure to perform impairment testing despite significant operational reductions.Inventory is currently understated as the company failed to include direct labor and manufacturing overheads in its valuation.Trade receivables, other financial assets, and bank balances are subject to pending confirmations and reconciliations.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company faces severe financial instability, negligible revenues, and multiple auditor qualifications regarding its financial reporting. The lack of impairment testing and inventory discrepancies suggest significant risks to the carrying value of assets.
IMP Powers Reports Q3 Net Loss of ₹217 Lakhs; Auditor Issues Qualified Opinion
IMP Powers Limited reported a net loss of ₹217.10 Lakhs for the quarter ended December 31, 2025, widening from a loss of ₹108.64 Lakhs in the previous year's corresponding quarter. Total income for the quarter stood at ₹163.50 Lakhs, a decline from ₹181.60 Lakhs year-on-year. The statutory auditors have issued a qualified opinion, highlighting that the company failed to perform impairment testing despite significant operational reductions and ongoing losses. Furthermore, the company resumed manufacturing but failed to include direct labor and overheads in inventory valuation, leading to understated inventory figures.
முக்கிய அம்சங்கள்
Net loss widened to ₹217.10 Lakhs in Q3 FY26 compared to ₹108.64 Lakhs in Q3 FY25.Total income for the quarter decreased to ₹163.50 Lakhs from ₹181.60 Lakhs year-on-year.Auditors issued a qualified opinion citing lack of impairment testing on assets despite indicators of potential impairment.Inventory valuation for the quarter excluded direct labor and manufacturing overheads, resulting in understated inventory and potentially overstated expenses.Trade receivables, other financial assets, and bank balances are subject to pending confirmations and reconciliations.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company continues to report losses and faces significant auditor qualifications regarding asset valuation and financial reconciliations. The lack of impairment testing and inventory valuation issues suggest that the reported financial position may not accurately reflect the underlying asset quality.
Neuland Labs Q3FY26 Revenue Up 11.4% to ₹447.8 Cr; EBITDA Margin Dips to 19%
Neuland Laboratories reported an 11.4% YoY increase in total income to INR 447.8 crores for Q3FY26, with the CMS (CDMO) segment contributing over 50% of revenue. EBITDA margins compressed to 19% from previous highs, primarily due to a shift in product mix and a one-time INR 10 crore impact from labor codes. Despite a significant 9-month capex of INR 254 crores, the company maintains a strong net cash position of INR 202.6 crores. Management noted that the absence of a specific high-margin CMS product shipment and delays in Paliperidone contributed to the quarterly margin dip.
முக்கிய அம்சங்கள்
Total income grew 11.4% YoY to INR 447.8 crores, driven by commercial CMS projects.EBITDA margin stood at 19%; adjusted for a INR 10 crore labor code impact, the margin would be 21%.9-month gross margin remains healthy at 56% compared to 55% in the previous year.Significant 9-month capex of INR 254 crores funded largely through internal accruals and customer advances.Working capital cycle stretched to 145 days due to higher inventories and uneven delivery flows.
👀 கவனிக்க வேண்டியவை
Investors should look past the quarterly margin volatility and focus on the successful ramp-up of expanded CMS capacity in Unit 3. The company's transition toward complex molecules and peptides remains the primary long-term value driver.
Mukand Ltd Q3 PAT at ₹17.21 Cr; Niraj Bajaj Re-appointed as CMD for 3 Years
Mukand Limited reported a standalone Profit After Tax (PAT) of ₹17.21 crore for the quarter ended December 31, 2025, a slight increase from ₹16.31 crore in the previous year. Total income for the quarter rose to ₹1,309.67 crore compared to ₹1,225.00 crore year-on-year. The board approved the re-appointment of Niraj Bajaj as Chairman and Managing Director and Nirav Bajaj as Whole-Time Director for three-year terms starting in 2026. Additionally, the company is progressing on a significant ₹673 crore land sale in Thane and a restructuring of its Industrial Machinery Division.
முக்கிய அம்சங்கள்
Standalone Total Income for Q3 FY26 rose to ₹1,309.67 crore from ₹1,225.00 crore YoY.Net Profit for the quarter stood at ₹17.21 crore, showing marginal growth from ₹16.31 crore in Q3 FY25.Company executed an agreement to sell land parcels in Thane for ₹673 crore, with ₹110 crore advance received.Niraj Bajaj re-appointed as CMD for 3 years effective July 5, 2026, ensuring leadership continuity.Industrial Machinery Division is being transferred to a wholly-owned subsidiary via slump sale for better operational focus.
👀 கவனிக்க வேண்டியவை
Investors should track the progress of the ₹673 crore land monetization as it will significantly improve the company's liquidity and debt profile. The leadership continuity is a positive sign, though the marginal growth in bottom-line profits warrants a cautious watch on operating margins.
Nandan Denim Q3 FY26 Net Profit Drops 55% YoY to ₹2.97 Crore; Revenue Slumps 46%
Nandan Denim Limited reported a significant downturn in its financial performance for the quarter ended December 31, 2025. Revenue from operations fell sharply by 46% year-on-year to ₹499.53 crore, while net profit declined by 55% to ₹2.97 crore compared to the same quarter last year. Sequentially, the results were even weaker, with net profit dropping from ₹9.45 crore in the preceding quarter. The company is also currently addressing regulatory penalties from BSE and NSE regarding non-compliance with board composition norms.
முக்கிய அம்சங்கள்
Revenue from operations decreased 46% YoY to ₹49,952.72 lakhs in Q3 FY26.Net profit for the quarter fell 55% YoY to ₹297.29 lakhs from ₹658.00 lakhs.Total expenses for the quarter stood at ₹49,687.45 lakhs, significantly lower than ₹91,937.22 lakhs YoY.The company has applied for a waiver of penalties levied by BSE and NSE for non-compliance with Regulation 17(1A).Nine-month net profit remains slightly higher at ₹2,361.89 lakhs compared to ₹2,284.90 lakhs in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the sharp decline in quarterly revenue and profitability suggests operational headwinds. Monitor the stock for management's explanation regarding the revenue contraction and the resolution of the regulatory penalty issue.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Windlas Biotech Q3 Revenue Up 20% to INR 233 Cr; Plant 6 Completion Set for FY26
Windlas Biotech reported a strong Q3 FY26 with revenue growing 20% YoY to INR 233 crores, marking its 12th consecutive quarter of record revenue. The CDMO vertical led the performance with 23% growth, while the Exports segment surged 36% due to increased penetration in semi-regulated markets. Management confirmed that Plant 6 is on track for mechanical completion by the end of FY26, which will bring the total revenue capacity to approximately INR 1,100 crores. For the first 9 months of FY26, the company achieved an EPS of INR 24.02, representing a 12% YoY increase.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 20% YoY to INR 233 Cr, while 9M FY26 revenue rose 19% to INR 666 Cr.9M FY26 EBITDA (excluding ESOP expenses) stood at INR 89 Cr with a margin of 13.3%.Exports vertical grew 36% in Q3 FY26, significantly outperforming domestic volume growth trends.Plant 6 mechanical completion expected by end of FY26 with an estimated capex of INR 50-60 Cr.Total revenue capacity target set at INR 1,000 Cr for oral solids and INR 100 Cr for injectables.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful commissioning and utilization of Plant 6 and the injectable facility as primary growth catalysts. The company's consistent 12-quarter revenue growth streak and expansion in high-margin exports make it a strong candidate for long-term portfolios in the CDMO space.
Windlas Biotech has received a Show Cause Notice from the Food Safety & Drug Administration (Uttarakhand), resulting in the temporary suspension of Codeine-containing cough syrup manufacturing. This specific product line contributed ₹55.21 crore to the company's total revenue in the current financial year as of February 9, 2026. While the suspension is limited to this product category, the company is preparing a detailed response to address the regulatory concerns and resume operations. Investors should monitor the duration of this suspension as it affects a material revenue stream.
முக்கிய அம்சங்கள்
Temporary suspension of Codeine-containing cough syrup manufacturing by Uttarakhand authorities.Affected product line contributed ₹55.21 crore to revenue in the current FY up to Feb 9, 2026.Suspension is limited to Codeine-based products; other manufacturing operations remain unaffected.Company is in the process of filing a detailed response to the Show Cause Notice within stipulated timelines.
👀 கவனிக்க வேண்டியவை
Investors should monitor the duration of the suspension as the affected revenue is significant. Watch for the company's formal response and any further regulatory actions or clearances from the Food Safety & Drug Administration.
Neuland Labs Q3FY26 Results: PAT Drops 60.2% YoY to Rs 40.4 Cr as Margins Contract
Neuland Laboratories reported a challenging Q3FY26 with a significant 60.2% YoY decline in Profit After Tax (PAT) to Rs 40.4 crore. While Total Income grew 11.4% YoY to Rs 447.8 crore, it fell 13.2% on a sequential basis. The company faced severe margin pressure, with EBITDA margins contracting to 19.0% from 30.4% in the previous quarter, driven by an unfavorable product mix and higher operating expenses. Management remains focused on long-term investments despite the current subdued profitability.
முக்கிய அம்சங்கள்
Total Income for Q3FY26 reached Rs 447.8 crore, up 11.4% YoY but down 13.2% QoQ.EBITDA fell 5.9% YoY and 45.8% QoQ to Rs 85.0 crore.EBITDA margins contracted sharply to 19.0%, down from 22.5% YoY and 30.4% QoQ.Profit After Tax (PAT) plummeted 60.2% YoY to Rs 40.4 crore compared to Rs 101.4 crore in Q3FY25.Management cited product mix shifts and increased operating expenses as primary reasons for subdued margins.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the sharp sequential decline in margins and profitability. It is essential to monitor management's guidance on the recovery of the product mix and the impact of ongoing investments on future earnings.
Windlas Biotech Re-appoints Founder and Two Independent Directors for 5-Year Terms
Windlas Biotech has approved the re-appointment of its founder, Mr. Ashok Kumar Windlass, as Whole-time Director for a five-year term starting May 2026. The board also re-appointed Chairman Mr. Vivek Dhariwal and Mr. Gaurav Gulati as Independent Directors for their second five-year terms. These moves ensure leadership continuity and maintain a board with deep expertise in pharmaceutical manufacturing and business strategy. The re-appointments are subject to shareholder approval and will extend the current leadership's tenure until 2031.
முக்கிய அம்சங்கள்
Mr. Ashok Kumar Windlass re-appointed as Whole-time Director for a 5-year term from May 3, 2026, to May 2, 2031.Chairman Vivek Dhariwal re-appointed as Independent Director for a second 5-year term starting May 6, 2026.Gaurav Gulati re-appointed as Independent Director for a second 5-year term starting May 6, 2026.The leadership team brings combined experience from major firms like Pfizer, Baxter, and Oyo Hotels.
👀 கவனிக்க வேண்டியவை
Investors should view this as a sign of management stability and continuity, which is beneficial for long-term strategic execution. No immediate action is required as the existing leadership remains in place.
Windlas Biotech Q3FY26: Revenue up 20% to Rs 233 Cr; 12th Consecutive Record Revenue Quarter
Windlas Biotech reported a strong 20% YoY revenue growth in Q3FY26, reaching Rs 233.1 crore, marking its 12th consecutive quarter of record revenue. While reported PAT for the quarter saw a marginal decline of 4% to Rs 14.9 crore due to non-cash ESOP expenses, adjusted PAT grew significantly. The core CDMO vertical, contributing over 70% of revenue, grew by 23% YoY, while the export segment surged by 36%. For the 9-month period, the company maintained healthy momentum with a 19% revenue increase and a 13% rise in reported PAT.
முக்கிய அம்சங்கள்
Revenue from operations grew 20% YoY to Rs 233.1 crore in Q3FY26, driven by the CDMO segment.Adjusted EBITDA (excluding ESOP expenses) for 9MFY26 rose 26% YoY to Rs 89 crore with a 13.3% margin.CDMO revenue increased 23% YoY in Q3FY26, contributing 71.6% to the total revenue mix.Export vertical showed significant traction with 36% YoY growth in Q3FY26, reaching Rs 13.2 crore.Plant-6 is on track for mechanical completion by the end of FY26, signaling future capacity expansion.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong 20% top-line growth and the robust performance of the CDMO segment, looking past the reported PAT dip caused by non-cash ESOP expenses. The consistent revenue records and upcoming capacity at Plant-6 suggest a positive long-term growth trajectory for the company.
Windlas Biotech Q3 Revenue Grows 19.5% YoY to ₹233 Cr; PAT Marginally Lower at ₹15 Cr
Windlas Biotech reported a 19.5% YoY increase in revenue for Q3 FY26, reaching ₹2,331.02 million. Despite the top-line growth, net profit declined slightly to ₹150.02 million from ₹155.76 million in the same quarter last year, impacted by a 30% rise in employee benefit expenses. For the nine-month period ending December 2025, the company maintained a positive trajectory with a 12.9% increase in net profit. The board also approved the dissolution of its non-operative US subsidiary to simplify the corporate structure.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue from Operations increased 19.5% YoY to ₹2,331.02 million.Net Profit for the quarter dipped 3.7% YoY to ₹150.02 million due to higher operating costs.9M FY26 Revenue reached ₹6,655.90 million, up from ₹5,571.73 million in the previous year.Employee benefit expenses surged to ₹420.48 million in Q3 FY26 compared to ₹321.72 million in Q3 FY25.Board approved the dissolution of Windlas Inc. USA, a non-operative wholly-owned subsidiary.
👀 கவனிக்க வேண்டியவை
While revenue growth is robust, the margin pressure from rising employee costs warrants caution; investors should hold for long-term CDMO prospects.
NDL Ventures Clarifies Q2 FY26 Filing Discrepancies; Reports Net Profit of ₹28.35 Lakh
NDL Ventures Limited has provided clarifications to the NSE regarding technical discrepancies in its Q2 FY26 financial filings, including machine-readability and segment reporting. The company reported a net profit of ₹28.35 lakh for the quarter ended September 30, 2025, up from ₹20.92 lakh in the corresponding quarter of the previous year. Total income for the quarter stood at ₹120.15 lakh, while the company maintains a single business segment in 'Other Financial Services'. A key ongoing development is the proposed merger with Hinduja Leyland Finance Limited, which has received a No Objection Certificate from the RBI.
முக்கிய அம்சங்கள்
Net Profit for Q2 FY26 increased to ₹28.35 lakh compared to ₹20.92 lakh in Q2 FY25.Total Income for the quarter was ₹120.15 lakh, a slight decrease from ₹124.23 lakh YoY.Company confirmed it operates as a single segment entity under 'Other Financial Services'.RBI has granted a No Objection Certificate (NOC) for the merger of Hinduja Leyland Finance Limited into the company.Cash and bank balances as of September 30, 2025, stood at ₹506.67 lakh.
👀 கவனிக்க வேண்டியவை
Investors should focus on the progress of the Hinduja Leyland Finance merger as it is the primary catalyst for the company's future valuation. The current standalone financials are relatively small and the regulatory clarifications are procedural in nature.
Raymond Lifestyle Q3 FY26 Revenue Hits Record INR 1,883 Cr; EBITDA Up 23% YoY
Raymond Lifestyle reported its highest-ever quarterly revenue of INR 1,883 crores in Q3 FY26, driven by strong festive and wedding season demand. EBITDA grew 23% YoY to INR 271 crores, with margins expanding significantly to 14.4% from 12.3% in the previous year. The company maintains a robust balance sheet with net debt effectively at INR 15 crores and net cash of INR 155 crores. Management is successfully executing a premiumization strategy, evidenced by a INR 26 per meter increase in average selling prices.
முக்கிய அம்சங்கள்
Record quarterly revenue of INR 1,883 crores with EBITDA margins expanding 210 bps to 14.4%9M FY26 revenue grew 9% to INR 5,223 crores, while EBITDA rose 18% to INR 652 croresAverage selling price (ASP) increased by INR 26 per meter, reflecting successful product mix improvementStrategic reduction in US market dependency from 50% to 35% to mitigate tariff uncertaintiesStrong liquidity position with net cash of INR 155 crores and net debt of only INR 15 crores
👀 கவனிக்க வேண்டியவை
Investors should take note of the record revenue and margin expansion as evidence of strong brand equity and operational efficiency. The proactive diversification of the export portfolio and low debt levels make it a resilient play in the lifestyle segment.
IMP Powers Responds to SEBI; New Management Seeks Revocation of Trading Suspension
IMP Powers Limited has been acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal Shah through an IBBI e-auction process. The new management has informed the exchange that they cannot provide clarifications on financial results for the quarter ended March 31, 2024, as those filings were managed by the Liquidator's office. Following an NCLT Ahmedabad order dated November 5, 2024, which granted specific reliefs, the company has requested the exchange to revoke the suspension of trading. The company is also seeking the listing of new shares to be allotted under the acquisition terms.
முக்கிய அம்சங்கள்
Company acquired as a going concern under Regulation 32(e) of IBBI Regulations by Electrify Energy Private Limited.NCLT Ahmedabad order dated November 5, 2024, granted reliefs and concessions to the successful auction purchasers.New management unable to clarify March 2024 financial reporting as it was handled by the Liquidator.Formal request for revocation of trading suspension and listing of new shares submitted on January 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the exchange's decision on the revocation of trading suspension and the specific terms of the new share allotment. The stock remains high-risk as it transitions from liquidation to new management control.
IMP Powers Clarifies Financial Reporting Status Following Liquidation and Ownership Change
IMP Powers Limited has responded to the Exchange's clarification request regarding financial results from May 2023. The company was acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal Shah through an e-auction under IBBI Liquidation Regulations. The new management stated they cannot comment on past reporting as it was handled by the Liquidator's office. The company has already approached the exchange to revoke the trading suspension and list new shares following an NCLT order dated November 5, 2024.
முக்கிய அம்சங்கள்
Company acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal ShahNCLT Ahmedabad order dated 05.11.2024 granted specific reliefs and concessions to the new ownersManagement unable to clarify May 2023 financial results as data remains with the Liquidator's officeFormal request submitted to the Exchange on 31.01.2025 for revocation of trading suspensionNew shares are pending allotment and listing as per the cited NCLT order
👀 கவனிக்க வேண்டியவை
Investors should monitor the Exchange's response regarding the revocation of the trading suspension and the listing of new shares. The stock remains a high-risk 'watch' as the company transitions from liquidation back to active operations.
Raymond Lifestyle Q3FY26: EBITDA Grows 23% to ₹271 Cr; Domestic Demand Offsets Export Weakness
Raymond Lifestyle reported a 5% YoY increase in total income to ₹1,883 Cr for Q3FY26, driven by strong domestic performance in Branded Textiles which grew 11%. EBITDA saw a significant jump of 23% to ₹271 Cr, with margins expanding by 210 bps to 14.4% due to a better product mix and operating leverage. However, the Garmenting segment revenue fell 17% YoY to ₹258 Cr due to US tariff uncertainties and weak international order books. The company maintains a healthy balance sheet with net debt at just ₹15 Cr and a total retail footprint of 1,675 stores.
முக்கிய அம்சங்கள்
Total Income grew 5% YoY to ₹1,883 Cr, while EBITDA rose 23% to ₹271 Cr in Q3FY26.Branded Textile segment revenue increased 11% to ₹951 Cr with a robust 21.8% EBITDA margin.Garmenting revenue declined 17% to ₹258 Cr due to global headwinds and US tariff uncertainty.Retail network expanded to 1,675 stores with 21 new openings and 9 exits during the quarter.Net Profit before exceptional items rose 54% to ₹100 Cr, though a ₹57 Cr labor code provision impacted final results.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong margin expansion in the domestic textile business and monitor the recovery in the garmenting export segment. The company remains a solid play on the Indian wedding and festive consumption cycle with a very lean balance sheet.
Raymond Lifestyle Appoints Prasad Ellatch Chathuar as CFO; 28 Years Experience
Raymond Lifestyle Limited has appointed Mr. Prasad Ellatch Chathuar as the Chief Financial Officer effective January 27, 2026. He succeeds Mr. Vishal Raigagla, who had been serving as the Interim CFO since October 29, 2025. Mr. Chathuar is a seasoned professional with 28 years of experience in the consumer industry, including a previous role as CFO at Bajaj Electricals Limited. This transition from an interim to a permanent, highly qualified CFO is expected to provide long-term stability to the company's financial leadership.
முக்கிய அம்சங்கள்
Mr. Prasad Ellatch Chathuar appointed as CFO and Key Managerial Personnel effective January 27, 2026.Brings 28 years of experience from Bajaj Electricals, Voltas (17 years), and Emami Paper Mills (5 years).Replaces Interim CFO Vishal Raigagla, who held the position since October 29, 2025.Educational qualifications include Chartered Accountant, Cost Accountant, and a Harvard University Executive Certification.
👀 கவனிக்க வேண்டியவை
The appointment of a permanent CFO with significant industry experience is a positive development for corporate governance. Investors should view this as a stabilizing move for the company's financial strategy and execution.
Raymond Lifestyle Q3 Revenue Up 9% to ₹1,466 Cr; Operating Margins Improve to 13.85%
Raymond Lifestyle reported a 9.4% YoY increase in standalone revenue to ₹1,466.23 crore for Q3 FY26. While operating margins improved significantly to 13.85% from 11.32% in the previous year, net profit for the quarter declined slightly to ₹49.45 crore due to a one-time exceptional loss of ₹42.68 crore. For the nine-month period ending December 2025, the company showed robust performance with net profit more than doubling to ₹112.94 crore. The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.11x.
முக்கிய அம்சங்கள்
Revenue from operations grew 9.4% YoY to ₹1,46,623 lakhs in Q3 FY26.Operating margin expanded to 13.85% in Q3 FY26 compared to 11.32% in Q3 FY25.Net profit for the nine-month period (9M FY26) surged to ₹11,294 lakhs from ₹5,549 lakhs YoY.Quarterly bottom line was impacted by an exceptional loss of ₹4,268 lakhs.Interest Service Coverage Ratio remains healthy at 4.59 for the quarter.
👀 கவனிக்க வேண்டியவை
Investors should look past the quarterly net profit dip caused by exceptional items and focus on the strong operational margin expansion and 9-month growth trajectory. The stock remains a watch for continued efficiency in the lifestyle segment.
NDL Ventures Q3 Net Profit Surges 254% YoY to ₹23.32 Lakhs; Merger with HLFL Progressing
NDL Ventures reported a strong year-on-year performance for the quarter ended December 31, 2025, with net profit rising to ₹23.32 lakhs from ₹6.59 lakhs in the previous year. Total income saw a steady increase to ₹126.08 lakhs compared to ₹116.70 lakhs in the same quarter last year. For the nine-month period, the company's profit reached ₹75.85 lakhs, a 68% increase over the previous year's ₹45.09 lakhs. A critical update for investors is the ongoing merger with Hinduja Leyland Finance Limited (HLFL), which has already received an RBI No Objection Certificate and is awaiting NCLT approval.
முக்கிய அம்சங்கள்
Net Profit for Q3 FY26 grew 254% YoY to ₹23.32 lakhs.Total Income for the quarter increased to ₹126.08 lakhs from ₹116.70 lakhs YoY.Nine-month (9M FY26) net profit stands at ₹75.85 lakhs, up from ₹45.09 lakhs in 9M FY25.The company has filed the draft 'Scheme of Merger by Absorption' of Hinduja Leyland Finance Limited with stock exchanges.Earnings Per Share (EPS) for the quarter improved to ₹0.07 from ₹0.02 in the corresponding quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the regulatory progress of the merger with Hinduja Leyland Finance, as this transaction will significantly transform the company's balance sheet and business operations. The standalone financial growth is positive but the merger remains the primary value driver.
Raymond Lifestyle Appoints Satyaki Ghosh as CEO to Lead Growth Transformation
Raymond Lifestyle Limited has appointed Satyaki Ghosh as its new Chief Executive Officer to spearhead its next phase of growth and transformation. Mr. Ghosh brings over 25 years of extensive experience in FMCG and textiles, having previously served as CEO of Cellulosic Fashion Yarn at Grasim Industries and in leadership roles at L’Oréal India. This strategic appointment, alongside the recent onboarding of E.C. Prasad as CFO, indicates a significant strengthening of the top management team. The company aims to leverage his expertise to expand its retail footprint, which currently includes over 1,650 stores across 600 cities.
முக்கிய அம்சங்கள்
Satyaki Ghosh appointed as CEO with 25+ years of experience across FMCG, textiles, and retail sectors.Previously held CEO roles at Aditya Birla Group (Grasim) and senior leadership positions at L’Oréal India.Appointment follows the recent hiring of E.C. Prasad as the company's new Chief Financial Officer.Raymond Lifestyle operates a vast retail network of 1,650+ exclusive stores across 600 cities and towns.The leadership change is aimed at driving operational excellence and capturing growth in domestic and international markets.
👀 கவனிக்க வேண்டியவை
Investors should view this high-profile hiring from a major competitor as a positive move towards professionalizing management and driving growth. Monitor upcoming earnings calls for the new CEO's strategic roadmap for the lifestyle and apparel business.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
